Document is current

Article History

Received: 28 September 2020

Accepted: 8 April 2021

First Online: 22 April 2021

Declarations

:

: Dr. Abul-Husn was previously employed by Regeneron Pharmaceuticals and has received a speaker honorarium from Genentech. E.E.K. has received speaker honoraria from Illumina and Regeneron Pharmaceuticals. The remaining authors have no relevant financial or non-financial interests to disclose.

: The Icahn School of Medicine at Mount Sinai’s Institutional Review Board approved this study (protocol number 18-1771), including a waiver of informed consent and a HIPAA waiver of authorization. The study population consisted of 30,223 participants aged 18 years or older from Mount Sinai’s Bio<i>Me</i> Biobank (protocol number 07-0529). This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: All participants of the Mount Sinai Bio<i>Me</i> Biobank provided written informed consent.

: All expected pathogenic variants in <i>CDH1</i> are reported in this paper. Exome sequencing and genotyping of Bio<i>Me</i> was performed in collaboration with the Regeneron Genetics Center. Individual-level data generated via this collaboration are not publicly available due to the terms of the Bio<i>Me</i> biospecimen and data access agreement but may be requested directly from the corresponding author.